Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Holdings

2,389.08
+22.540.95%
Number of Gainers:68
Number of Losers:26
Number of Flat:3
PE:- -
High:2,396.41
Open:2,366.62
Low:2,366.55
Close:2,366.54
Volume:1.30B
Turnover:281.66B
Market Cap:52.92T
Float Cap:49.57T

Loading ...

Breaking: Jensen Huang Set to Take On Role at Tsinghua University

Deep News
·
Sep 30

Silo Pharma Unit QwikAgents Adds Nvidia Nemotron Model Support

Reuters
·
Sep 30

Silo Pharma’s Qwikagents Expands AI Agent Platform with Nvidia Model Support and New Runtime Flexibility

THOMSON REUTERS
·
Sep 30

Health Care Select Sector SPDR: Pivot points

TIPRANKS
·
Sep 30

CTS Eventim AG & Co. KGaA (0EEE) Gets a Buy from J.P. Morgan

TIPRANKS
·
Sep 30

UBS Sticks to Its Hold Rating for Apple (AAPL)

TIPRANKS
·
Sep 30

Tesla's Cash Crunch Has Arrived-Blame Its AI Ambitions

Dow Jones
·
Sep 30

Harmonic Launches Recon Network Monitoring Product Family Developed With Comcast

MT Newswires Live
·
Sep 30

Amazon Price Target Raised to $360.00/Share from $335.00 by Rosenblatt

Dow Jones
·
Sep 30

Apple Set to Launch Smart Home Hub with Voice Recognition and Recipe Lookup, Plus Personalized Interface Switching

Deep News
·
Sep 30

TSMC Reportedly Weighs Texas Expansion as Second Major U.S. Chip Hub

Stock News
·
Sep 30

Global bond markets suffer worst September in years as US Treasury yields hit highest since 2007, yet stocks stay surprisingly resilient

Deep News
·
Sep 30

KIDZ AI Plans Autonomous Fleet Operations Strategy Tied to Potential 500 Tesla Robotaxi Acquisition

Reuters
·
Sep 30

Abbott announces U.S. commercial launch of SimpleScreen CRC

TIPRANKS
·
Sep 30

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Sep 30

Eli Lilly - 77% of Ebglyss Patients Reported Satisfaction with Hand Clearance at Week 16

THOMSON REUTERS
·
Sep 30

Eli Lilly - Ebglyss Monotherapy Meets Primary and Secondary Endpoints at Week 16 in Phase 3B Adtouch Study

THOMSON REUTERS
·
Sep 30

New Phase 3B Data Show Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Significant and Rapid Improvements in Skin Clearance, Itch, Pain, and Patient Satisfaction in People with Moderate-to-Severe Hand and Foot Atopic Dermatitis

THOMSON REUTERS
·
Sep 30

Eli Lilly - Treatment-Emergent Adverse Events in 41.8% Ebglyss Patients, 39.6% Placebo, All Mild or Moderate

THOMSON REUTERS
·
Sep 30

Eli Lilly - Submits Ebglyss Adtouch Data to FDA and Plans Global Regulatory Submissions for Label Update

THOMSON REUTERS
·
Sep 30